Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.06. | Day One Biopharmaceuticals, Inc.: Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development | 5 | GlobeNewswire (USA) | ||
03.06. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
06.05. | Day One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
06.05. | Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2025 Financial Results and Corporate Progress | 270 | GlobeNewswire (Europe) | OJEMDA (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in... ► Artikel lesen | |
06.05. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
22.04. | Day One Biopharmaceuticals, Inc.: Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025 | 7 | GlobeNewswire (USA) | ||
03.04. | H.C. Wainwright maintains Buy on Day One Biopharmaceuticals | 9 | Investing.com | ||
06.03. | Day One Biopharmaceuticals, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
26.02. | Day One Biopharmaceuticals stock target cut to $36 at H.C. Wainwright | 8 | Investing.com | ||
25.02. | Day One Biopharmaceuticals GAAP EPS of -$1.02 misses by $0.29, revenue of $131.16M beats by $8.64M | 2 | Seeking Alpha | ||
25.02. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.02. | Day One Biopharmaceuticals, Inc.: Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025 | 7 | GlobeNewswire (USA) | ||
23.01. | Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now? | 13 | Insider Monkey | ||
13.01. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
10.01. | Day One Biopharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
30.10.24 | Day One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2024 Financial Results and Corporate Progress | 395 | GlobeNewswire (Europe) | Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call... ► Artikel lesen | |
30.07.24 | Day One Biopharmaceuticals, Inc.: Day One Reports Second Quarter 2024 Financial Results and Corporate Progress | 375 | GlobeNewswire (Europe) | Achieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch Expanded pipeline with DAY301, potential first-in-class Antibody Drug Conjugate (ADC) targeting... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 92,45 | -0,11 % | Renk Aktie: Die große Wende? - Dazu: Biontech, Deutsche Telekom, Hensoldt, NAGA, Rheinmetall - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
CUREVAC | 4,692 | -0,42 % | Milliardenmarkt: BioNTech, CureVac & Moderna: Welches Unternehmen gewinnt das mRNA-Rennen? | © Foto: picture alliance/dpa | Bernd WeißbrodWährend sich BioNTech, CureVac und Moderna zu Beginn ähnlich entwickelten, zeichnet sich aktuell ein Gewinner ab. Die Marktwirtschaft und der mit ihr einhergehende... ► Artikel lesen | |
AMGEN | 250,90 | -0,16 % | Lilly, Novo, and Amgen set for key obesity trial readouts at upcoming ADA event | ||
NOVAVAX | 5,584 | +0,23 % | Novavax slips as Citi launches with Sell rating on pipeline concerns | ||
BIOGEN | 110,05 | -0,23 % | Ihre wichtigsten Termine: Alle Analysten-Augen auf: Biogen, Etsy, Westwing, Bike24, FMC und AdCapital | © Foto: Biogen - biogen.comGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:30... ► Artikel lesen | |
CRISPR THERAPEUTICS | 38,600 | +0,52 % | Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? | ||
MAINZ BIOMED | 2,775 | -100,00 % | Mainz Biomed Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
VIKING THERAPEUTICS | 22,495 | -0,38 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25
Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 7,854 | -1,53 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy ... | With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 8,726 | -0,48 % | BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report | ||
TEMPUS AI | 59,22 | -0,20 % | Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building? | ||
SAREPTA THERAPEUTICS | 17,410 | -0,31 % | Sarepta-Aktie crasht erneut: Weiterer Todesfall | Aktionäre der Biotech-Gesellschaft Sarepta Therapeutics müssen einen weiteren Rückschlag hinnehmen. Am Wochenende berichtete das Unternehmen und sein Pharma-Partner Roche über einen weiteren Todesfall... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 1,078 | -0,74 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,085 | -1,26 % | PacBio Board Independent Investigation Concludes Allegations Unsubstantiated | MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent... ► Artikel lesen | |
EXELIXIS | 34,880 | -0,54 % | Exelixis, Inc.: Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors | - A regulatory decision by the European Medicines Agency is anticipated in 2025 - - In March 2025, the U.S. Food and Drug Administration approved CABOMETYX in this setting - Exelixis, Inc.... ► Artikel lesen |